GTC Biotherapeutics (fka GTCB)

[raistthemage]

The business plan seems to be diluting the existing shareholders every time the company needs money rather then cutting funding on any of their existing programs, or god forbid cutting management compensation (like they are doing a good job and deserve it). There are possibly good reasons why they can't get a partnership (especially on favorable terms), there are none why they won't trim the burn rate. A painless way to trim it would be to get rid of the entire management except for Meade.

Rejection of the reverse split will soon have the effect of having the company live within its European Atryn HD revenue, which is what we need. Hopefully Cox will be removed too.